Navigation Links
Unilife Corporation Commences Trading on the NASDAQ Global Market Under the Ticker Symbol 'UNIS'
Date:2/16/2010

LEWISBERRY, Pa., Feb. 16 /PRNewswire-FirstCall/ -- Unilife Corporation (Company) ( UNIS, ASX: UNS) today announced that the Company's common stock began trading on the NASDAQ Global Market on Tuesday, February 16, 2010, under the ticker symbol "UNIS."

"This is a major step for Unilife Corporation, signifying the completion of its transition from the Australian Stock Exchange into a publicly listed U.S. company.  I believe moving the Company to the U.S. and listing our common stock on a major international exchange complements our rapid emergence as a global leader for innovative safety medical devices," stated Alan Shortall, CEO of Unilife.

Investors wishing to trade on either the NASDAQ or ASX are invited to visit the Company's website (www.unilife.com) to access information on Unilife Corporation, including a list of Frequently Asked Questions. The Company has also opened an Investor Hotline to assist with shareholder inquiries. The inquiry hotline numbers are 1-800-632-680 (Australia toll free), +1-866-496-5819 (US toll free) and or +61 2 8256 3394 (International).

Unilife is also pleased to advise that CEO Alan Shortall will preside over the NASDAQ closing bell ceremony on Monday, February 22, 2010. Members of Unilife's management team and guests will join Mr. Shortall at the ceremony, which will take place at the NASDAQ MarketSite in Times Square and will be broadcast live.

About Unilife Corporation

Unilife Corporation is a U.S.-based medical device company focused on the design, development, manufacture and supply of a proprietary range of retractable syringes. Primary target customers for Unilife products include pharmaceutical manufacturers, suppliers of medical equipment to healthcare facilities and patients who self-administer prescription medication. These patent-protected syringes incorporate automatic and fully-integrated safety features which are designed to protect those at risk of needlestick injuries and unsafe injection practices. Unilife is ISO 13485 certified and has FDA-registered medical device manufacturing facilities in Pennsylvania.

Unilife's main product is the Unifill™ ready-to-fill syringe, which is designed to be supplied to pharmaceutical manufacturers in a form that is ready for filling with injectable drugs and vaccines. Unilife has a strategic partnership with sanofi-aventis, a large global pharmaceutical company, pursuant to which it has paid Unilife a euro 10 million exclusivity fee and has committed to pay up to an additional euro 17 million to fund an industrialization program for the Unifill™ syringe. Upon the scheduled completion of the industrialization program in late 2010, Unilife expects to commence the supply and sale of the Unifill™ syringe to sanofi-aventis. Unilife is also in discussions with other pharmaceutical companies that are seeking to obtain access to the Unifill™ syringe.

This press release contains forward-looking statements. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These forward-looking statements are based on management's beliefs and assumptions and on information currently available to our management. Our management believes that these forward-looking statements are reasonable as and when made. However, you should not place undue reliance on any such forward-looking statements because such statements speak only as of the date when made. We do not undertake any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. In addition, forward-looking statements are subject to certain risks and uncertainties that could cause actual results, events and developments to differ materially from our historical experience and our present expectations or projections. These risks and uncertainties include, but are not limited to, those described in "Item 1A. Risk Factors" and elsewhere in our registration statement on Form 10 and those described from time to time in our future reports which we will file with the Securities and Exchange Commission. 

    
    
    Investor Contacts (US):
    Todd Fromer / Garth Russell                   Stuart Fine
    KCSA Strategic Communications                 Carpe DM Inc
    Phone + 1 212-682-6300                        Phone + 1 908 469 1788
    
    Investor Contacts (Australia)
    Jeff Carter
    Unilife Corporation
    Phone + 61 2 8346 6500

SOURCE Unilife Corporation

RELATED LINKS
http://www.unilife.com

'/>"/>

SOURCE Unilife Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. CEL-SCI Corporation Reports First Quarter 2010 Financial Results
2. Volcano Corporation Completes Acquisition of Lumen Biomedicals Xtract(TM) Thrombus Aspiration Catheter
3. World Heart Corporation Announces the Election of a New Director
4. Volcano Corporation Announces Litigation Status
5. Oxford Finance Corporation Closes $25 Million Credit Facility with EUSA Pharma
6. Vystar Corporation Engages The Investor Relations Group
7. Techne Corporation Declares Dividend
8. ETEX Corporation Announces Distribution Agreement With OrthoPediatrics Corp.
9. Laerdal Medical and Medical Simulation Corporation Partner to Offer Integrated Training Courses for SimMan(R) Patient Simulators
10. Providence Service Corporation to Present at the Sidoti & Company, LLC Micro Cap Conference on Monday, January 11th and at the CJS Securities New Ideas for the New Year Conference on Thursday, January 14th
11. LOREAL and Hurel Corporation Announce R&D Collaboration to Develop a Non-Animal Alternative, Microfluidic Biochip
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... Cryoablation, Electrical, Endometrial Hydrothermal, Laser/Light, Microwave, Radiofrequency, Ultrasound, Cardiovascular, Gynaecology, ... expected to grow at a CAGR of 9.4% from 2017-2022 and ... at a CAGR of 9.5% from 2017 to 2027. The market ... ... benefit you Read on to discover how you can exploit ...
(Date:2/17/2017)... 2017 Arvinas LLC, a private biotechnology company ... degradation, today announced the presentation of new preclinical data ... poster session at the American Society of Clinical Oncology ... Orlando, FL. "The new ... the potential of PROTACs to drive durable and robust ...
(Date:2/17/2017)... and Markets has announced the addition of the "Pharmaceutical Contract Manufacturing ... ... the US, Canada , Japan , ... of World. Annual estimates and forecasts are provided for the period 2015 ... Market data and analytics are derived from primary and secondary research. ...
Breaking Medicine Technology:
(Date:2/17/2017)... FL (PRWEB) , ... February 17, 2017 , ... ... software tools that allow for the electronic prescribing of controlled and non-controlled substances ... , Ninety percent of pharmacies in the United States now accept electronic prescriptions, ...
(Date:2/17/2017)... ... February 17, 2017 , ... Empowering each person's mental functions, ... each and every seminar, session and class she offers. At the International ... which help energize creativity, focus mental functions, enhance athletic focus and skill sets, ...
(Date:2/17/2017)... , ... February 17, 2017 , ... ... the HIMSS17 Conference & Exhibition in Orlando, Fla., February 19-23. Visitors to the ... the most widely used electronic patient signatures solution in healthcare . ...
(Date:2/17/2017)... ... February 17, 2017 , ... Pharmica Consulting attended ... all facets of clinical trial planning and management. Pharmica discussed the importance of ... In addition, attendees stopping by Pharmica’s booth were able to demo its cloud-based ...
(Date:2/17/2017)... ... 17, 2017 , ... Like most hospitals across the nation, Onslow Memorial Hospital ... the Hospital Readmission Reduction Program (HRRP), the return of a patient to the hospital ... the nation. While many providers are struggling to leverage limited resources and technology, Onslow ...
Breaking Medicine News(10 mins):